|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NOP53 |
Gene summary for NOP53 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NOP53 | Gene ID | 29997 |
| Gene name | NOP53 ribosome biogenesis factor | |
| Gene Alias | GLTSCR2 | |
| Cytomap | 19q13.33 | |
| Gene Type | protein-coding | GO ID | GO:0000027 | UniProtAcc | Q9NZM5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 29997 | NOP53 | GSM4909281 | Human | Breast | IDC | 2.59e-17 | -1.95e-01 | 0.21 |
| 29997 | NOP53 | GSM4909282 | Human | Breast | IDC | 1.33e-16 | -4.27e-01 | -0.0288 |
| 29997 | NOP53 | GSM4909285 | Human | Breast | IDC | 1.01e-26 | 9.00e-02 | 0.21 |
| 29997 | NOP53 | GSM4909286 | Human | Breast | IDC | 5.34e-29 | 6.51e-01 | 0.1081 |
| 29997 | NOP53 | GSM4909287 | Human | Breast | IDC | 4.59e-08 | -4.97e-01 | 0.2057 |
| 29997 | NOP53 | GSM4909290 | Human | Breast | IDC | 1.74e-05 | -2.74e-01 | 0.2096 |
| 29997 | NOP53 | GSM4909293 | Human | Breast | IDC | 3.04e-30 | -4.66e-01 | 0.1581 |
| 29997 | NOP53 | GSM4909294 | Human | Breast | IDC | 3.09e-19 | -6.15e-01 | 0.2022 |
| 29997 | NOP53 | GSM4909296 | Human | Breast | IDC | 3.40e-02 | -3.38e-01 | 0.1524 |
| 29997 | NOP53 | GSM4909298 | Human | Breast | IDC | 2.52e-21 | 1.92e-01 | 0.1551 |
| 29997 | NOP53 | GSM4909299 | Human | Breast | IDC | 1.92e-11 | 3.45e-01 | 0.035 |
| 29997 | NOP53 | GSM4909300 | Human | Breast | IDC | 1.58e-03 | 3.79e-01 | 0.0334 |
| 29997 | NOP53 | GSM4909301 | Human | Breast | IDC | 8.87e-12 | -4.52e-01 | 0.1577 |
| 29997 | NOP53 | GSM4909304 | Human | Breast | IDC | 2.19e-27 | -5.62e-01 | 0.1636 |
| 29997 | NOP53 | GSM4909305 | Human | Breast | IDC | 2.57e-20 | 6.04e-01 | 0.0436 |
| 29997 | NOP53 | GSM4909306 | Human | Breast | IDC | 7.83e-08 | 1.64e-01 | 0.1564 |
| 29997 | NOP53 | GSM4909307 | Human | Breast | IDC | 1.20e-03 | -1.48e-02 | 0.1569 |
| 29997 | NOP53 | GSM4909308 | Human | Breast | IDC | 2.35e-24 | 2.05e-01 | 0.158 |
| 29997 | NOP53 | GSM4909311 | Human | Breast | IDC | 2.43e-17 | -2.17e-01 | 0.1534 |
| 29997 | NOP53 | GSM4909313 | Human | Breast | IDC | 8.45e-04 | 3.70e-01 | 0.0391 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004477213 | Endometrium | EEC | mitotic cell cycle phase transition | 71/2168 | 424/18723 | 8.68e-04 | 7.97e-03 | 71 |
| GO:003953111 | Endometrium | EEC | regulation of viral-induced cytoplasmic pattern recognition receptor signaling pathway | 9/2168 | 24/18723 | 9.45e-04 | 8.45e-03 | 9 |
| GO:003952811 | Endometrium | EEC | cytoplasmic pattern recognition receptor signaling pathway in response to virus | 11/2168 | 34/18723 | 1.10e-03 | 9.48e-03 | 11 |
| GO:009008512 | Endometrium | EEC | regulation of protein deubiquitination | 6/2168 | 12/18723 | 1.19e-03 | 1.00e-02 | 6 |
| GO:009858611 | Endometrium | EEC | cellular response to virus | 20/2168 | 84/18723 | 1.21e-03 | 1.02e-02 | 20 |
| GO:000222112 | Endometrium | EEC | pattern recognition receptor signaling pathway | 34/2168 | 172/18723 | 1.22e-03 | 1.02e-02 | 34 |
| GO:006220712 | Endometrium | EEC | regulation of pattern recognition receptor signaling pathway | 23/2168 | 105/18723 | 1.81e-03 | 1.41e-02 | 23 |
| GO:007145314 | Endometrium | EEC | cellular response to oxygen levels | 34/2168 | 177/18723 | 2.02e-03 | 1.53e-02 | 34 |
| GO:004349113 | Endometrium | EEC | protein kinase B signaling | 38/2168 | 211/18723 | 3.74e-03 | 2.49e-02 | 38 |
| GO:005189612 | Endometrium | EEC | regulation of protein kinase B signaling | 34/2168 | 185/18723 | 4.24e-03 | 2.75e-02 | 34 |
| GO:003447012 | Endometrium | EEC | ncRNA processing | 63/2168 | 395/18723 | 5.20e-03 | 3.26e-02 | 63 |
| GO:003629414 | Endometrium | EEC | cellular response to decreased oxygen levels | 30/2168 | 161/18723 | 5.66e-03 | 3.40e-02 | 30 |
| GO:19017971 | Endometrium | EEC | negative regulation of signal transduction by p53 class mediator | 9/2168 | 31/18723 | 6.90e-03 | 3.98e-02 | 9 |
| GO:00714567 | Endometrium | EEC | cellular response to hypoxia | 28/2168 | 151/18723 | 7.84e-03 | 4.36e-02 | 28 |
| GO:00073467 | Endometrium | EEC | regulation of mitotic cell cycle | 70/2168 | 457/18723 | 8.76e-03 | 4.74e-02 | 70 |
| GO:002261327 | Esophagus | HGIN | ribonucleoprotein complex biogenesis | 158/2587 | 463/18723 | 2.61e-29 | 5.23e-26 | 158 |
| GO:000906020 | Esophagus | HGIN | aerobic respiration | 81/2587 | 189/18723 | 1.07e-22 | 9.26e-20 | 81 |
| GO:000609120 | Esophagus | HGIN | generation of precursor metabolites and energy | 145/2587 | 490/18723 | 3.41e-20 | 2.04e-17 | 145 |
| GO:004533320 | Esophagus | HGIN | cellular respiration | 86/2587 | 230/18723 | 2.41e-19 | 1.20e-16 | 86 |
| GO:004225426 | Esophagus | HGIN | ribosome biogenesis | 101/2587 | 299/18723 | 8.74e-19 | 4.03e-16 | 101 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |